Friday 23 March 2018

Progress towards identifying immunotherapy targets for IDH1-mutant low grade glioma

Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma
click here for abstract.

"By analyzing the repertoire of T-cell target antigens in IDH mut glioma patients, we identified five novel immunogenic TAAs [tumor associated antigens] and confirmed their expression on IDH mut tumors and GSCs [glioma stem cells]."
Posted by at
Labels: , ,

3 comments:

  1. Matjaz11 July 2018 at 07:50

    Don't know where else to post this:

    Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
    https://www.nature.com/articles/s41591-018-0095-6

    Sci-Hub link (working at the moment):
    https://sci-hub.tw/https://www.nature.com/articles/s41591-018-0095-6

    Another evidence that IDH1 mutation is immunosuppresive. In discussion, the authors write: "Moreover, clinical studies applying checkpoint
    blockade or specific immune interventions such as IDH1R132H-
    specific vaccines may be more effective when combined with IDH
    inhibitors."

    I hope there will be some trials combining IDH1 inhibitors and immunotherapy in near future.

    ReplyDelete
    Replies
    1. Stephen W11 July 2018 at 12:06

      Me too, I've been waiting for such trials for over a year, since this was published:

      https://www.ncbi.nlm.nih.gov/pubmed/28319047

      Delete
    2. Stephen W16 July 2018 at 15:11

      Here's another one:

      http://sci-hub.tw/http://clincancerres.aacrjournals.org/content/early/2018/07/13/1078-0432.CCR-17-3855.full-text.pdf

      The oncometabolite D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas that inhibits both complement and T cells

      Delete

Subscribe to: Post Comments (Atom)